A Phase 1 interventional study of Ziresovir and Placebo in Healthy Subjects, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-15.
Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.
Up to 3 dose cohorts are planned. The ziresovir dose level of each cohort is determined based on the collective clinical and nonclinical data of ziresovir.
The proposed dose levels of Cohorts 1, 2 and 3 are 300 mg and up to 600 mg and up to 900 mg, respectively.
A total of up to 24 subjects will be randomized with 18 subjects to receive active drug and 6 subjects to receive placebo in a double-blind fashion. Eight subjects will be randomized in each dose cohort, with 6 subjects to receive active drug and 2 subjects o receive placebo.
Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast. Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows: * If administered 60 mL as the study drug dose, follow with approximately 180 mL water. * If administered 120 mL as the study drug dose, follow with approximately 120 mL water. * If administered 180 mL as the study drug dose, follow with approximately 60 mL water.
Drug: Ziresovir
The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast. Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows: * If administered 60 mL as the study drug dose, follow with approximately 180 mL water. * If administered 120 mL as the study drug dose, follow with approximately 120 mL water. * If administered 180 mL as the study drug dose, follow with approximately 60 mL water.
Other: Placebo
Planned treatments are: * Cohort 1: 300 mg of ziresovir * Cohort 2: up to 600 mg of ziresovir * Cohort 3: up to 900 mg of ziresovir
Also known as: AK0529
Planned treatments are: * Cohort 1: 300 mg of placebo * Cohort 2: up to 600 mg of placebo * Cohort 3: up to 900 mg of placebo
numbers of all AEs
The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs
Time frame: through study completion, an average of 22 days
percentages of all AEs
The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs
Time frame: through study completion, an average of 22 days
change from baseline in systolic and diastolic blood pressure
blood pressure in millimeter of mercury
Time frame: screen/day -1/day 1/day 2/day 3/day4
change from baseline in pulse rate
pulse rate in times per minute
Time frame: screen/day -1/day 1/day 2/day 3/day4
change from baseline in respiratory rate
respiratory rate in times per minute
Time frame: screen/day -1/day 1/day 2/day 3/day4
change from baseline in oral temperature
oral temperature in degree
Time frame: screen/day -1/day 1/day 2/day 3/day4
change from baseline in Prothrombin time/International Normalized Ratio
INR is calculated from the PT and allows for worldwide standardization of results.
Time frame: screen/day -1/day 2/day4
change from baseline in Thrombin time
Thrombin time in seconds
Time frame: screen/day -1/day 2/day4
change from baseline in activated Partial Thromboplastin time
activated Partial Thromboplastin time in seconds
Time frame: screen/day -1/day 2/day4
change from baseline in Hemoglobin (Hgb) count
Hemoglobin (Hgb) in gram per liter
Time frame: screen/day -1/day 2/day4
change from baseline in Hematocrit (Hct)
Time frame: screen/day -1/day 2/day4
change from baseline in Platelet count
Platelet count per liter
Time frame: screen/day -1/day 2/day4
change from baseline in Red blood cell (RBC) count
Time frame: screen/day -1/day 2/day4
change from baseline in White blood cell (WBC) count with differential
Time frame: screen/day -1/day 2/day4
change from baseline in Specific gravity from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in pH from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in Protein from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in Glucose from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in Ketones from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in Bilirubin from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in Blood from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in Nitrites from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in Leukocytes from urinalysis
Time frame: screen/day -1/day 2/day4
change from baseline in Urobilinogen from urinalysis
Time frame: screen/day -1/day 2/day4
Incidence of abnormal Microscopic urine analysis
Time frame: screen/day -1/day 2/day4
change from baseline in heart rate-corrected QT interval from resting 12-lead ECGs
ECGs will be performed after the subject has been supine for at least 5 minutes
Time frame: screen/day -1/day1/day2/day4
change from baseline in heart rate from resting 12-lead ECGs
ECGs will be performed after the subject has been supine for at least 5 minutes
Time frame: screen/day -1/day1/day2/day4
change from baseline in QRS intervals from resting 12-lead ECGs
ECGs will be performed after the subject has been supine for at least 5 minutes
Time frame: screen/day -1/day1/day2/day4
change from baseline in treatment-emergent T-wave morphology from resting 12-lead ECGs
ECGs will be performed after the subject has been supine for at least 5 minutes
Time frame: screen/day -1/day1/day2/day4
change from baseline in appearance of U-waves from resting 12-lead ECGs
ECGs will be performed after the subject has been supine for at least 5 minutes
Time frame: screen/day -1/day1/day2/day4
Incidence of abnormal physical findings
full physical examination will be conducted at screening and an abbreviated physical exam will be conducted on Day -1 and Day 2. A symptom-directed physical exam will be conducted on Day 3 and Day 4.
Time frame: screen/day -1/day2/day3/day4
To characterize the drug concentration of ziresovir following single ascending doses by oral administration in healthy adult male and female subjects
Time frame: 0 (within 90 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2021 to primary completion in Jun 2021, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziresovir
Shanghai Ark Biopharmaceutical Co., Ltd.